Paul Hanna, MD, MSc

Publications

• Cardiovascular involvement in ANCA-associated vasculitis.

  (Sarmad A, Gholizadeh Ghozloujeh Z, Hanna PE, Kronbichler A, Geetha D, Heidari-Bateni G, Mathew R, Ahmad M, Mohammed A, Siddiqui S, Abdipour A, Norouzi S.) Nephrol Dial Transplant. 2025 Nov 26;40(12):2256-2267 PMID: 40280728 SCOPUS ID: 2-s2.0-105022928511 04/26/2025

• Nephrotoxicity of Conventional Chemotherapeutics: Part I - Platinum Compounds and Antimetabolite Agents.

  (Kelly A, Sharma S, Mamlouk O, Hassanein M, Chowdhury R, Gupta S, Troung H, Bonilla M, Kalra K, Wanchoo R, Pariswala T, Turcotte AE, Zaveri I, Dernell C, Ibrahim M, Patel M, Eskander SS, Gudsoorkar P, Jhaveri KD, Perazella MA, Hanna PE.) Nephrol Dial Transplant. 2025 Nov 17 PMID: 41247096 11/17/2025

• Comparative safety of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in patients receiving anti-neoplastic therapies for cancer: An inverse probability treatment weighting analysis.

  (Lyu J, Specht K, Seiglie JA, Ouyang T, Mistry K, Seethapathy H, Zubiri L, Khor SY, Hanna PE, Cao A, Moreno D, Mejia SM, Gupta S, Sise ME.) Cancer Lett. 2025 Nov 01;632:217958 PMID: 40738413 SCOPUS ID: 2-s2.0-105012130094 07/31/2025

• Nephrotoxicity of Conventional Chemotherapeutics: Part II - Non-Platinum Agents and Miscellaneous Nephrotoxic Drugs.

  (Kelly A, Sharma S, Mamlouk O, Hassanein M, Chowdhury R, Gupta S, Truong H, Bonilla M, Kalra K, Wanchoo R, Pariswala T, Turcotte AE, Zaveri I, Dernell C, Ibrahim M, Patel M, Eskander SS, Gudsoorkar P, Jhaveri KD, Perazella MA, Hanna PE.) Nephrol Dial Transplant. 2025 Oct 17 PMID: 41105138 10/17/2025

• Clinical Implications of Striated Nephrogram in Patients Receiving Immune Checkpoint Inhibitors for Cancer.

  (Moreno D, Hanna PE, Mistry K, Heidari P, Sise ME, Seethapathy H.) Kidney Med. 2025 Aug;7(8):101038 PMID: 40740732 PMCID: PMC12304893 07/31/2025

• Sarcopenia, Elevated Body Mass Index, and Platinum-Associated Adverse Events in Patients With Lung Cancer.

  (Lyu J, Mantz L, Katz-Agranov NS, Ouyang T, Hanna PE, Mejia SM, Moreno D, Lee M, Cao A, Dinulos JE, Cosar D, Shaker M, Shah SJ, Gainor JF, Temel JS, Lei M, Inker LA, Fintelmann FJ, Sise ME.) J Natl Compr Canc Netw. 2025 Jul 30;23(9):393-400 PMID: 40738140 SCOPUS ID: 2-s2.0-105015792212 07/31/2025

• Use of SGLT2 inhibition in the management of hyponatremia in a patient with metastatic cancer

  (Eilis Eschweiler, Anna Gaddy, and Paul E. Hanna.) Journal of Onconephrology. 12/17/2025

• Eculizumab use in drug-induced thrombotic microangiopathy with CFHR1–CFHR3 deletion

  (Vinay Srinivasan, Ellen Cody, Margaret DeOliveira, and Paul E Hanna .) Journal of Onconephrology. 12/02/2025

• Idiopathic Nodular Glomerulosclerosis in a Long-term Passive Smoker With Recently Diagnosed Hypertension: A Case Report.

  (Vakhshoori M, Hanna PE, Obaidi Z, Chen Wongworawat Y, Abdipour A, Norouzi S.) J Investig Med High Impact Case Rep. 2025;13:23247096251323066 PMID: 40069965 PMCID: PMC11898078 03/12/2025

• Immune Checkpoint Inhibitor–Associated Acute Kidney Injury

  (Marta Pirovano, Paul E. Hanna, Mohamed Hassanein, Shruti Gupta .) StatPearls. 01/17/2025

• Risk Factors for Severe Hypertension and Proteinuria After Treatment With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Among Patients With Cancer.

  (Hanna PE, Anumolu RK, Motwani SS, Chen KL, Katz-Agranov N, Green-Lingren O, Yilmam OA, Jhaveri KD, Kitchlu A, Kala J, Sise ME, Gupta S.) Kidney Int Rep. 2024 Jun;9(6):1897-1902 PMID: 38899179 PMCID: PMC11184235 06/20/2024

• Risk Factors for Severe Hypertension and Proteinuria After Treatment With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Among Patients With Cancer

  (Hanna PE, Anumolu RK, Motwani SS, Chen KL, Katz-Agranov N, Green-Lingren O, Yilmam OA, Jhaveri KD, Kitchlu A, Kala J, Sise ME, Gupta S.) Kidney International Reports. June 2024;9(6):1897-1902 SCOPUS ID: 2-s2.0-85189238641 06/01/2024